DIAGNOS Appoints New Chairman of the Board of Directors
September 25 2019 - 10:09AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the appointment of Mr.
François Côté as Chairman of the Corporation’s board of directors
(the “Board”), effective today, in replacement of Mr. Georges
Hébert who will remain a member of the Board. The Corporation also
announces stock option grants to its directors and officers.
“I am pleased that François has accepted the
role of Chairman of the Board. His great knowledge of the
healthcare industry and his business relationships will continue
benefitting DIAGNOS. As I remain a director of the Corporation,
François can count on my support and the support of my fellow
directors”, said Mr. Georges Hébert, outgoing chairman of the
Board. The appointment of Mr. Côté to the Board was initially
announced on June 18, 2019.
The Board has approved a grant totalling
2,250,000 stock options to its directors and officers. Stock
options vest at 50% per year, commencing with the first anniversary
of the grant. The exercise price of these options has been
established at $0.20 per share. The expiry date to which these
options can be exercised has been fixed to September 25, 2024.
The Corporation also announces that it has
received final acceptance from the TSX Venture for (i) the
amendment to its stock option plan (the “Plan”) pursuant to which
the maximum number of common shares of the Corporation that may be
issued under the Plan be set at 6,000,000, as detailed in the
September 20, 2019 announcement on the voting results of the annual
and special meeting of shareholders, and (ii) a private placement
for gross receipts of $550,000, as detailed in the September 16,
2019 announcement on the closing of the private placement.
All monies quoted in this press release shall be
stated and paid in lawful money of Canada.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Sep 2023 to Sep 2024